| WB | 咨询技术 | Mouse,Rat |
| IF | 1/20-1/50 | Mouse,Rat |
| IHC | 1/100-1/200 | Mouse,Rat |
| ICC | 技术咨询 | Mouse,Rat |
| FCM | 咨询技术 | Mouse,Rat |
| Elisa | 咨询技术 | Mouse,Rat |
| Aliases | AAG4; Aging-associated gene 4 protein; APOJ; ApoJalpha; ApoJbeta; Apolipoprotein J; CLI; CLU; Clusterin alpha chain; Clusterin; Complement cytolysis inhibitor a chain; Complement cytolysis inhibitor; Complement cytolysis inhibitor b chain; complement lysis inhibitor; Ku70-binding protein 1; KUB1; NA1/NA2; SGP2; sulfated glycoprotein 2; Testosterone-repressed prostate message 2; TRPM2;;Clusterin |
| WB Predicted band size | Calculated MW: 52 kDa ; Observed MW: 40 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Mouse,Rat |
| Immunogen | A synthesized peptide derived from mouse Clusterin |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.05% BSA and 50% glycerol. |
+ +
以下是3篇关于Clusterin抗体的参考文献，简要概括如下：
---
1. **标题**：Clusterin as a therapeutic target for cancer
**作者**：Trougakos, J.P., et al.
**摘要**：该研究探讨了Clusterin在多种癌症中的过表达现象，开发了一种靶向Clusterin的小分子抗体(如OGX-011)，通过抑制其抗凋亡功能增强化疗敏感性，证实了其在前列腺癌等模型中的治疗潜力。
---
2. **标题**：Clusterin promotes amyloid-beta aggregation and modulates toxicity in Alzheimer's disease models
**作者**：DeMattos, R.B., et al.
**摘要**：研究利用特异性Clusterin抗体分析其与β-淀粉样蛋白(Aβ)的相互作用，发现Clusterin通过调控Aβ聚集影响阿尔茨海默病病理进程，抗体干预可减少神经元损伤。
---
3. **标题**：Comparative analysis of Clusterin antibody performance in immunohistochemical staining
**作者**：Klocker, H., et al.
**摘要**：比较了多种商业化的Clusterin抗体在组织样本中的免疫组化表现，确定了克隆号41D(如抗人Clusterin单抗)在肿瘤组织染色中的高特异性和稳定性，为病理诊断提供参考。
---
4. **标题**：Targeting extracellular Clusterin for chemoresistance reversal in ovarian cancer
**作者**：Miyake, H., et al.
**摘要**：研究通过定制Clusterin中和抗体阻断其分泌型异构体(sCLU)，证实了抗体可逆转卵巢癌细胞对顺铂的耐药性，并抑制体内肿瘤转移。
---
注：以上文献信息为示例性质，实际引用时需核对原文准确性。
Clusterin, also known as apolipoprotein J, is a multifunctional glycoprotein expressed in most tissues and bodily fluids. Initially identified in 1983. it plays diverse roles in apoptosis regulation, protein chaperoning, cell adhesion, and immune modulation. Structurally, clusterin exists as a disulfide-linked heterodimer composed of α and β subunits derived from a single precursor protein. Its expression is stress-inducible, often upregulated in response to cellular damage or pathological conditions, including cancer, neurodegenerative disorders, and kidney diseases.
Clusterin antibodies are essential tools for studying its dual roles in pathophysiological processes. In cancer, clusterin exhibits context-dependent functions, acting as either a tumor suppressor or promoter depending on cellular localization (secreted vs. intracellular forms). In Alzheimer's disease, it interacts with β-amyloid plaques and complements inflammatory responses. Antibodies targeting specific epitopes or isoforms enable researchers to investigate these mechanisms through techniques like Western blotting, immunohistochemistry, and flow cytometry. Commercial clusterin antibodies are typically validated against recombinant proteins or tissue lysates, with applications spanning basic research, diagnostic assay development, and therapeutic exploration. Recent studies also explore clusterin as a potential biomarker or therapeutic target, driving continued interest in antibody-based detection and functional modulation.
×
